Orum Therapeutics

Orum Therapeutics is an antibody-based drug developer founded in 2016 by CEO Lee Seung-joo, formerly of LG Life Sciences, and is described as the first company worldwide to pioneer degrader-antibody conjugates (DAC), which attach targeted protein degradation payloads to antibodies.

The company brands this approach dual-precision targeted protein degradation (TPD-squared), aiming to overcome both the limited payload mechanisms of conventional antibody-drug conjugates and the narrow therapeutic index of small-molecule degraders.

Research is split between headquarters in Daejeon, which handles antibody development, and a Boston laboratory responsible for chemistry and ADC work, with clinical trials run mainly in the United States.

The revenue model is licensing rather than product sales: the company states in its quarterly report that its standard deal structure combines an upfront payment, development milestones and post-launch royalties.

In November 2023 it transferred ORM-6151, an acute myeloid leukemia (AML) asset, to BMS for up to USD 180 million, of which USD 100 million was a non-refundable upfront.

In 2024 it signed a platform agreement with Vertex Pharmaceuticals granting rights to up to three targets, with reported terms of up to USD 310 million in milestones per target and a USD 15 million upfront, for aggregate potential value in the trillion-won range.

Its wholly owned pipeline now consists of ORM-1153 for AML and ORM-1023 for small cell lung cancer, after breast cancer candidate ORM-5029, the lead asset at the time of listing, was voluntarily withdrawn from a U.S. Phase 1 following a serious adverse event.

Competition spans the global ADC and TPD field, and in the CD123 space targeted by ORM-1153, AbbVie's pivekimab is an antibody-drug conjugate already further along in development.

Structurally, therefore, revenue clusters around deal signings and milestone achievements, while the intervening periods carry research spending only, the classic profile of a clinical-stage biotech.

The annual pattern shows the full amplitude of licensing accounting. In 2023 revenue was KRW 135.4 billion, operating profit KRW 95.6 billion and net profit KRW 68.2 billion, for an operating margin of 70.6 percent, reflecting concentrated recognition of the BMS upfront.

In 2024 revenue fell to KRW 20.9 billion, turning to an operating loss of KRW 8.3 billion and a net loss of KRW 5.7 billion, and in 2025 revenue was only KRW 23.6 million, with the operating loss widening sharply to KRW 51.8 billion and the net loss to KRW 42.0 billion.

One outlet reported that milestone and new upfront receipts assumed in the IPO prospectus did not materialize in 2025, leaving revenue at about KRW 23.6 million for the year.

Quarterly data tell the same story: revenue was KRW 4.2 million in 2Q25, KRW 15.9 million in 3Q25, KRW 0.6 million in 4Q25, zero in 1Q26 and KRW 24.1 million in 2Q26, effectively a blank line, while the operating loss moved from KRW 10.0 billion in 2Q25 to KRW 13.9 billion, KRW 18.3 billion, KRW 18.1 billion and KRW 15.4 billion as clinical preparation costs accumulated.

Notably, in 2Q26 the company reported an operating loss of KRW 15.4 billion yet net profit attributable to owners of KRW 63.4 billion, which by definition means the bottom-line swing came from non-operating items rather than business activity.

The company's quarterly report notes that issued preferred shares are classified as liabilities under IFRS, creating a gap between paid-in capital in the statement of changes in equity and the balance sheet, indicating a structure in which preferred-share-related valuation items can flow through earnings.

On balance-sheet strength, the debt-to-equity ratio was negative in 2023 amid a capital deficit, then turned positive after listing and stayed low at 26.3 percent in 2024 and 29.4 percent in 2025.

Operating cash flow was an inflow of KRW 94.2 billion in 2023 but became outflows of KRW 11.3 billion in 2024 and KRW 36.0 billion in 2025, confirming that cash drains steadily in periods without licensing receipts.

DAC combines the targeted delivery of antibodies with the catalytic mechanism of protein degraders and is presented as a way to improve on the toxicity, resistance and target limitations of conventional ADC payloads.

In investor materials the company said its platform showed potential in preclinical work for reduced systemic toxicity, higher intratumoral activity, improved pharmacokinetics and a wider therapeutic index.

The sector's core bottleneck remains toxicity: although solid tumors account for about 90 percent of all cancers, development crowds into blood cancers because solid tumors demand high doses or strongly cytotoxic agents and carry off-target toxicity risk.

Orum's own lead asset at listing targeted a solid tumor indication, breast cancer, but its trial was halted after liver toxicity emerged, and industry observers have framed this as an issue common to solid-tumor oncology drugs rather than company-specific.

Development focus has since shifted to hematologic cancers, and analysts note that CD123, the target of ORM-1153, extends beyond AML to indications such as myelodysplastic syndrome.

On competitive positioning, the company announced at AACR 2026 that ORM-1153 showed superior preclinical efficacy versus AbbVie's pivekimab.

On the cost side, an industry source explained that a single preclinical round for a DAC runs about KRW 20 billion, with more than KRW 10 billion per asset per year once trials begin.

The cycle in this segment is therefore driven not by unit sales but by three event types: conference data, regulatory clearances and big-pharma deals.

The clearest confirmed catalyst is the pipeline's return to the clinic. The company announced in August 2026 that the U.S.

FDA had cleared the investigational new drug application for ORM-1153, its CD123-GSPT1 DAC, and said it plans to begin a first-in-human Phase 1 in relapsed or refractory AML and other blood cancers by the end of 2026.

That Phase 1 is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity.

Partner-led work runs in parallel: BMS is reported to be enrolling a target of 105 AML and myelodysplastic syndrome patients in the ORM-6151 Phase 1, exploring recommended doses as monotherapy, in doublet combination with azacitidine and in triplet combination with azacitidine and venetoclax, with primary completion expected in February 2027 and full study end in 2030.

In April 2026 a site in Seville, Spain was reportedly added, broadening patient recruitment geography. For the second in-house asset, ORM-1023 in small cell lung cancer, reports indicate a plan to fix the development candidate and pursue out-licensing after conference presentation of the data.

The gap versus the financial roadmap presented at listing is a separate item to monitor: the company was reported to have projected 2026 revenue of KRW 75.2 billion and operating profit of KRW 31.5 billion in its IPO filing, whereas confirmed results show first-half 2026 revenue of only about KRW 24 million.

On funding, a KRW 145 billion convertible preferred stock round led by KB Investment closed in December 2025, and the company said proceeds would advance pipeline programs including ORM-1153, develop new payload classes beyond GSPT1 and support additional targeted DAC programs.